Two signalling molecules recruit immune cells known as "killer" T cells to a specific type of colon cancer with more favourable patient outcomes, a University of Alberta researcher has report, and the finding may represent a therapeutic strategy to target other types of cancers.
Dr Kristi Baker, assistant professor in the Department of Oncology, examined tumours from patients with mismatch repair deficient colorectal cancer, a type that affects about 10 to 15 per cent of patients. While 85 per cent of colorectal cancers come from polyps, the mismatch repair deficient subset is developed through a different set of mutations. She report her findings in the paper, ‘ Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10’, published in the Journal of Experimental Medicine.
"All cancer cells have a lot of mutations, but this particular group has a significantly higher number—almost tenfold as much as some of the other cancers," said Baker, who is also a member of the Cancer Research Institute of Northern Alberta and the Women and Children's Health Research Institute.
That higher number of mutations is what gives patients with the mismatch repair deficient tumours more positive outcomes in general. The immune system can sometimes overlook tumours because they look so similar to normal cells, so they are not recognised as something foreign that needs to be attacked. However, the higher number of mutations in mismatch repair deficient tumours means they're very visible to the immune system.
"They're naturally able to attract these killer T cells into the tumour," said Baker. "So, patients with this type of cancer do better even without immune therapies, because they tend to have a lot of these tumour-killing T cells already inside the tumour, and if you add immunotherapy on top of that, it gives them a huge boost."
Unfortunately, said Baker, only a fraction of patients actually respond to immunotherapy treatments and typically, it's the patients who already have those cells in place inside the tumour.
To make immunotherapy effective for a larger population, there needs to be a way to recruit those cancer-killing T cells into the tumour, she explained.
One of the ways the body directs immune cells to areas when needed is through the secretion of a type of signalling protein called chemokines. Each particular chemokine attracts a slightly different combination of cells, and after they sound the alarm in the body, the immune cells flood to that area where the chemokines are most concentrated.
The two chemokines Baker and her team looked at, CCL5 and CXCL10, were previously found to have the potential to recruit killer T cells in a tumour environment, but this is the first time they have been shown to be effective with this particular type of cancer. It is also the first time it has been shown that the tumour cells are able to produce the chemokines.
The next step for Baker and her team is to further explore how the T cells become activated when they land inside the tumour, and how to improve that process.
"I like to use the analogy that T cells are kind of like drug-sniffing dogs: they need to be trained as to what they're supposed to target," said Baker. She plans to look further at a particular cell type, dendritic cells, which are "instructional" cells that help train T cells to recognize what they need to react against.
Some preliminary data from the Baker lab show that dendritic cells in mismatch repair deficient tumours are more effective at the training process. By understanding why, the hope is that the effectiveness can be duplicated in other types of cancer cells.
"We're trying to find more generic, widely applicable ways to transfer the good prognosis we see in these mismatch repair deficient cancers into the other types of cancer," said Baker.